|Year : 2017 | Volume
| Issue : 2 | Page : 136
Novel insight on probiotic Bacillus subtilis: Mechanism of action and clinical applications
Manoj A Suva, Varun P Sureja, Dharmesh B Kheni
Department of Pharmacology, K. B. Institute of Pharmaceutical Education and Research, Kadi Sarva Vishwavidyalaya University, Gandhinagar, Gujarat, India
|Date of Web Publication||8-Jan-2018|
Mr. Manoj A Suva
Department of Pharmacology, K. B. Institute of Pharmaceutical Education and Research, Kadi Sarva Vishwavidyalaya University, Gandhinagar - 382 024, Gujarat
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Suva MA, Sureja VP, Kheni DB. Novel insight on probiotic Bacillus subtilis: Mechanism of action and clinical applications. J Curr Res Sci Med 2017;3:136
|How to cite this URL:|
Suva MA, Sureja VP, Kheni DB. Novel insight on probiotic Bacillus subtilis: Mechanism of action and clinical applications. J Curr Res Sci Med [serial online] 2017 [cited 2018 Jan 20];3:136. Available from: http://www.jcrsmed.org/text.asp?2017/3/2/136/222418
We would like to highlight recent information on the previous report on “Novel insight on probiotic Bacillus subtilis: Mechanism of action and clinical applications.”B. subtilis spores act as probiotic by possible mechanisms as mentioned in previous report include antimicrobial effect by synthesis of antimicrobial substances, antidiarrheal effect, immunostimulatory effect, competitive exclusion of pathogens, prevention of intestinal inflammation, and normalization of intestinal flora. However, in previous article, exact antidiarrheal mechanism and clinical safety profile of B. subtilis was not mentioned. Recent evidences show that B. subtilis CU1 strain is capable of acting directly on diarrhea by inhibiting the cystic fibrosis transmembrane conductance regulator (CFTR) expression (transporters involved in the secretion of water) and inducing the Na +/H + exchanger 3 (NHE-3) expression (transporters involved in the absorption of water) in the colon and thereby regulates the fluidity of intestinal tract and exerts potent antidiarrheal action. Hence, B. subtilis CU1 probiotic strain can be used for treatment and or/prevention of diarrhea. According to European Food Safety Authority Qualified Presumption of Safety approach and Joint Food and Agriculture Organization of the United Nations/WHO guidelines, B. subtilis CU1 is identified at the strain and species level, using combination of genomic testing techniques and through random amplified polymorphic DNA polymerase chain reaction and pulsed-field gel electrophoresis analyses, to be lacking transferable antimicrobial resistances and toxigenic activity. Safety evaluations, bothin vitro and clinical study, demonstrated that B. subtilis CU1 strain is a nonpathogenic and nontoxicogenic strain of B. subtilis; safe and well-tolerated in healthy controls at 2 × 109 spores/day for total study period of 4 months (for initial 10 days of every month repeatedly) without any undesirable physiological effects on markers of liver and kidney function, complete blood counts, hemodynamic parameters, and vital signs. Hence, B. subtilis can be considered as a promising probiotic for managing various clinical conditions in humans with utmost safety profile.
| References|| |
Suva MA, Sureja VP, Kheni DB. Novel insight on probiotic Bacillus subtilis
: Mechanism of action and clinical applications. J Curr Res Sci Med 2016;2:65-72. [Full text]
Huu MK, Fioramonti J, Urdaci M, Inventor; Lesaffre and Company, National Institute of Agronomic Research (INRA), National School of Agricultural Sciences of Bordeaux Aquitaine (Bordeaux), Assignee. Probiotic Strains for Treating and/or Preventing Diarrhea. United States Patent US 2016/0000840 A1; 2016.
Lefevre M, Racedo SM, Denayrolles M, Ripert G, Desfougères T, Lobach AR, et al.
Safety assessment of Bacillus subtilis
CU1 for use as a probiotic in humans. Regul Toxicol Pharmacol 2017;83:54-65.